Connect with us

Public Companies

Microdose’s Molecular Masterclass Takes Deep Dive Into DMT Therapeutics

The article Microdose’s Molecular Masterclass Takes Deep Dive Into DMT Therapeutics was originally published on Microdose.

Want to catch all your favorite…



The article Microdose’s Molecular Masterclass Takes Deep Dive Into DMT Therapeutics was originally published on Microdose.

Want to catch all your favorite psychedelic companies and speakers at the premiere LIVE psychedelic event this fall? Then get your tickets to #WonderlandMiami today! Tickets range from online admission to special VIP access tickets.

Described as the “spirit molecule”, the mysteriously powerful psychedelic drug dimethyltryptamine (DMT) is re-emerging in this modern renaissance in a big way and was the focus of our most recent Molecular Masterclass.

We’d like to thank our headline sponsor, Small Pharma, as well as our other passionate partners who made this possible: Entheon Biomedical, Pharmadrug, Algernon Pharmaceuticals along with our world-class clinicians, scientists, and researchers.

Check out this short six-minute clip from the conference featuring Dr. Andrew Hegle of Entheon Biomedical!

What is DMT?

Dimethyltryptamine (DMT) is a powerful hallucinogenic compound in the tryptamine family of psychedelic compounds. It is found in several plants, is produced endogenously in the body, and the pure molecule can also be synthesized in a laboratory. The popular Amazonian psychedelic brew Ayahuasca contains DMT as its primary psychoactive compound. Other preparations include an unrefined mixture of plants/flowers that contain DMT that is known as “changa” and is smoked.

However, the companies, scientists, and speakers featured at this latest Masterclass are taking these traditional forms of DMT to new levels with next-generation products and practices, like in-clinic IV DMT, pharmahuasca, novel analogs, unique delivery methods, and much more on the horizon.

While a different molecule in the DMT family, the uniquely powerful hallucinogen 5-MeO-DMT, is also explored in this conference by Joël Brierri, founder of Kaivalya Kollectv and Symbiosis Retreats, along with Tricia Eastman, Rak Razam, Merrill Ward, Dr. Joseph Barsuglia, all leading experts and practitioner in working with 5-MeO-DMT

Want to learn more about this mysterious molecule? Be sure to read the DMT edition of our #MeetTheMolecule series: “What is DMT? An Evidence-based review”.

Masterclass: The Best and Brightest Minds Working with DMT

Along with the bright minds at Small Pharma, represented by Peter Rands and Graham Pechenik, that headlined our conference, we’d like to extend a huge thanks to our additional sponsors, Entheon Biomedical, Algernon Pharmaceuticals, and Psilera Biosciences who made this possible and provided incredible insight into the world of DMT therapeutics.

Along with the luminaries representing our sponsors, we hosted another roster of world-class speakers, such as Carol Routledge, Brian Jahns, Andrew Hegle, Paul Van Slyke, and Natan Ponieman as the moderator for the panel on DMT drug delivery & safety panel.

Not Just About the Science: Exploring Business & Markets as it Relates to DMT

Our law and policy experts, David Wood, Ruth Chun, Hadas Alterman, Sasha Sisko, all offered important insights into DMT, during the law and regulations panel. Since DMT is a schedule-1 substance and restricted across most of the world, this panel had some particularly important takeaways.

The renowned Rick Strassman delivered a beautiful presentation on his panel “DMT is Everywhere: Past, Present, and Future”. Rockstar leadership from Entheon such as Brian Jahn and Timothy Ko, CBO and CEO of Entheon respectively, spoke to their efforts while the dynamic Nadia Van der Hayden, Director of Sales & Marketing at Psygen Labs, spoke brilliantly on the Business & Markets panels they shared Be sure to check out the recording if you missed it!

A Brief Snapshot & Key Highlights From the Conference

Entheon Explores the Neuroscience of DMT

Thanks to you, our dedicated audience and partners, for making this Molecular Masterclass result in the highest attendance and engagement of all our molecular masterclass conferences. The day kicked off with Entheon Biomedical exploring the neuroscience and clinical potential of DMT as a therapeutic.

For instance, Christopher Timmermann provided an intriguing theory based on the fact that in many experiences hallucinating highly geometric visuals (which he describes as ‘tunnels, Cyprus, lattices, and cobwebs’) is consistent across subjects, to a degree. He believes ‘this suggests that these geometries are actually manifestations of the primary visual cortex there, or somehow manifesting, the structure of the brain.’

While he acknowledges it’s a radical idea that somehow, instead of looking outwards, we’re starting to look inside of our brains instead, Timmerman believes further research could indeed reveal this.

Learn more about Entheon by catching their highlights at their last Psychedelic Capital presentation here.

Entheon Elucidates Evidence for DMT’S Neurogenesis and Neuroprotective Effects

Along with evaluating the significance of the subjective psychedelic experience, their team is also exploring the neurogenesis and neuroprotective effects of DMT in the body, which are mediated by the via Sigma one receptors that can lead to powerful inflammatory and anti-ischemic properties. Indeed, applications are currently underway to potentially use DMT for stroke.

So there’s a lot of exciting potential for DMT Both fascinating avenues of research the Entheon Team is sure to continue pursuing this important exploration into how these drugs work in the brain

PharmaDrug Opens the Conversation About Non-Psychiatric Medical Use

While psychedelics hold immense potential to treat the mentally ill, however, the buck doesn’t stop there. The aforementioned neurogenesis and neuroprotective properties expressed by DMT are being apple to a variety of non-psychiatric applications. For instance, the Pharmadrug team is developing a 30 nanomolar intraocular (goes in the eye) DMT solution for glaucoma treatment. They are finding that such a minuscule dose (factors of hundreds below the threshold dose for psychoactivity) can regrow the necessary nerves to reverse glaucoma. The team is even working on an implant to insert into the eye that will consistently release nanomolar amounts of DMT into the eye regularly.

Having just listed under the ticker: PHRX on the Canadian Stock Exchange (CSE), Pharmadrug is ready to take advantage of psychedelic capital markets and we wish them luck!

Check out this recent press release by the PharmaDrug team announcing the filing of an orphan drug designation with the FDA for use in kidney transplants and other expanded applications!

Can DMT Help Stroke Patients? Algernon Pharmaceuticals is on Their Way to Find Out

​​The aforementioned neurogenesis and neuroprotective properties of DMT make it a versatile therapeutic that seems to have applications well beyond neuropsychiatry and the psychedelic experience. One company investigating DMT as a possible treatment for stroke in current phase 2 trials is Algernon Pharmaceuticals.

Due to its aforementioned properties of DMT to be able to regrow, repair, and protect neurons, Algernon is exploring the possibility of DMT being the next, highly efficacious generation of treatments for stroke patients, who currently have limited quality options. In a similar spirit, other plant medicines and psychedelics, such as ibogaine, are also being investigated for non-psychiatric use, such as in the treatment of Parkinson’s Disease. It is these novel applications of psychedelics we couldn’t develop in the 60s’ and ’70s since biotechnology still had a long way to go.

Today, combined with cutting-edge technology, companies like Algnernon are curating second-generation psychedelic medicines targeting a range of clinically important indications, not all of which revolve around mental illness.

Interested in exploring Algernon’s drug development and R&D efforts further? Check out this PsyCap recap from their last presentation at Psychedelic Capital.

Psilera Biosciences Looks Ahead to The Future of DMT in Mindful Medicine Practices

As a clinical biologist myself, with a genuine passion for neuropharmacology, I always enjoy when Jackie von Salm, Chief Science Officer, and Chris Witowski, Psilera CEO, present. Among their primary goals is to develop the next generation of psychedelic drugs that are more amenable and practical for the mainstream public, their healthcare practitioners, and insurance companies.

Find Jackie & Chris as interesting as I do? Check out each of their guest appearances on the PsyFi podcast!

Episode #5: PsyFi podcast ft. Pisilera Biosciences CEO, Dr. Chris WIitowski

Episode #7 PsyFi podcast ft. Psilera Biosciences CSO Dr. Jackie von Salm

Their team of advanced and experienced chemists is skilled at developing derivatives of traditional psychedelics to reduce psychoactivity, for instance, so they are more practical in an outpatient setting. By employing this strategy, the Psilera team hopes to bring insurers on board and provide maximum accessibility to these compounds for those who need it. They are currently incubated by the University of South Florida and have a collaboration with the Neuroscience Institute that specializes in alcohol addiction and circadian rhythm studies as well.

Exploring the Even More Powerful 5-MeO-DMT

Beyond N,N-DMT: Exploring the Even More Powerful 5-MeO-DMT

While traditional N, N-DMT, more commonly known simply as DMT, is a unique and powerful compound on its own, it is worth mentioning its cousin 5-MeO-DMT. This panel featured Joël Brierre, Tricia Eastman, Rak Razam, Merrill Ward, Dr. Joseph Barsuglia. Known as one of, if not the most powerful psychedelic drug known to man, 5-MeO-DMT is said to induce a state of non-duality, which is one of the most profound states of consciousness known to man. Increased cell proliferation, anti-addictive effects, and lasting anti-depressive effects are only a few of the many benefits associated. Unlike traditional psychedelics, 5-MeO-DMT acts more on the serotonin 1A and 7 system rather than the 5HT2A receptor system, which is the receptor generally known to produce those classic psychedelic effects caused by tryptamines.

Dr. Barsuglia went on to say that it has “Been hypothesized to be associated with consciousness depth of engendering depth of consciousness experiences and the Sigma receptors are connected to the anti-inflammatory and neuro regenerative properties of it, so there’s for sure in effect on radically altering consciousness and also a lot of potential for medical therapies, whether it’s pain, inflammation and a host of neurologic disorders as well, and I would say there’s a lot of observational research that had been done.

Dr. Barsuglia even went on to talk about a study he did involving 515 subjects that empirically showed 5-MeO-DMT is not addictive or habit-forming–valuable data that is sure to influence drug policy. He is also a vocal supporter of the mystical experience holding the real therapeutic value in all the purported benefits from the “5”.

Finally, practitioners Joël Brierre and Rak Razamalso had the real-world experience to share about how they have established the safest and best practices after years of training and thousands of administrations of medicine. 5-MeO-DMT and psychedelic expert Merrill Ward kindly shared his valuable insights as well. As the last panel to close this masterclass, we would like to thank all our sponsors, speakers, and, of course, our dedicated audience.

Hope to see you all in Miami, live, celebrate, and share deeper insights about this exciting movement.

Want to learn more about the seriously progressive company Psilera Biosciences? Check out their PsyCap Recap that captures the highlights from their presentation here.

Read More